Skip to main content

Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients

Introduction

Endotoxin plays a crucial role in the pathogenesis of severe sepsis and septic shock (SS&SSh) [1]. The aim of this study is to analyze the impact of extracorporeal endotoxin removal with polymyxin B hemoperfusion (PMX-DHP) (Toraymyxin®).

Methods

All patients admitted to our ICU between 1 April 2011 and 30 June 2013 who developed SS&SSh and underwent endotoxin activity assay (EAA) measurement were retrospectively evaluated.

Results

During the study period, EAA was dosed in 100 patients. Eighty- one patients were affected by septic shock. The source of infection was identified in 70.4% of cases (45% abdominal) and the percentage of microbiologically confirmed episodes was 77% (81% Gram-negatives). The mortality rate was 49%. The mean EAA level was 0.66 ± 0.2, and in 66% of patients the value was higher than 0.6. No significant differences were found in terms of SAPS II (P = 0.32) and SOFA score (P = 0.67), according to EAA level (>/≤0.6). Patients with levels >0.6 presented a higher percentage of microbiologically confirmed infections (84% vs. 66%; P = 0.09). Thirty-two of 66 patients with EAA >0.6 were treated with Toraymyxin®. No complications leading to treatment interruption were recorded and a relevant decrease of cardiovascular SOFA score and lactate levels were observed 72 hours after treatment (P = 0.05 and P = 0.06, respectively). Source control and Toraymyxin® treatment resulted as the only modifiable factors improving the ICU survival rate (Table 1).

Table 1 Multivariate analysis for ICU mortality risk factors

Conclusion

EAA is a rapid and reliable method to identify patients who may be treated with polymyxin B hemoperfusion. Source control and extracorporeal endotoxin removal have appeared as two effective interventions that should be implemented in the early management of patients with SS&SSh.

References

  1. 1.

    Cruz DN, Antonelli M, et al.: Early use of polymyxin B hemoperfusion in abdominal septic shock. The EUPHAS randomized controlled trial. JAMA 2009, 301: 2445-2452. 10.1001/jama.2009.856

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to SL Cutuli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cutuli, S., De Pascale, G., Alicino, V. et al. Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients. Crit Care 18, P408 (2014). https://doi.org/10.1186/cc13598

Download citation

Keywords

  • Survival Rate
  • Lactate
  • Effective Intervention
  • Septic Shock
  • Emergency Medicine